Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Integration of Tumor-Treating Fields into the Multidisciplinary Management of Patients with Solid Malignancies.

Wang Y, Pandey M, Ballo MT.

Oncologist. 2019 Aug 23. pii: theoncologist.2017-0603. doi: 10.1634/theoncologist.2017-0603. [Epub ahead of print] Review.

PMID:
31444292
2.

Tumor treating fields: a new frontier in cancer therapy.

Davies AM, Weinberg U, Palti Y.

Ann N Y Acad Sci. 2013 Jul;1291:86-95. doi: 10.1111/nyas.12112. Epub 2013 May 9. Review.

PMID:
23659608
3.

Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.

Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, Toms S, Idbaih A, Ahluwalia MS, Fink K, Di Meco F, Lieberman F, Zhu JJ, Stragliotto G, Tran D, Brem S, Hottinger A, Kirson ED, Lavy-Shahaf G, Weinberg U, Kim CY, Paek SH, Nicholas G, Bruna J, Hirte H, Weller M, Palti Y, Hegi ME, Ram Z.

JAMA. 2017 Dec 19;318(23):2306-2316. doi: 10.1001/jama.2017.18718. Erratum in: JAMA. 2018 May 1;319(17):1824.

4.

A Review on Tumor-Treating Fields (TTFields): Clinical Implications Inferred From Computational Modeling.

Wenger C, Miranda PC, Salvador R, Thielscher A, Bomzon Z, Giladi M, Mrugala MM, Korshoej AR.

IEEE Rev Biomed Eng. 2018;11:195-207. doi: 10.1109/RBME.2017.2765282. Epub 2018 Feb 13. Review.

PMID:
29993870
5.

Technological Advances in the Treatment of Cancer: Combining Modalities to Optimize Outcomes.

Wong ET, Toms SA, Ahluwalia MS.

Clin Adv Hematol Oncol. 2015 Nov;13(11 Suppl 11):1-18.

PMID:
26862770
6.

The Evolving Role of Tumor Treating Fields in Managing Glioblastoma: Guide for Oncologists.

Burri SH, Gondi V, Brown PD, Mehta MP.

Am J Clin Oncol. 2018 Feb;41(2):191-196. doi: 10.1097/COC.0000000000000395. Review.

7.

Tumor treating fields (TTFields) delay DNA damage repair following radiation treatment of glioma cells.

Giladi M, Munster M, Schneiderman RS, Voloshin T, Porat Y, Blat R, Zielinska-Chomej K, Hååg P, Bomzon Z, Kirson ED, Weinberg U, Viktorsson K, Lewensohn R, Palti Y.

Radiat Oncol. 2017 Dec 29;12(1):206. doi: 10.1186/s13014-017-0941-6.

8.

Tumor Treating Fields Technology: Alternating Electric Field Therapy for the Treatment of Solid Tumors.

Benson L.

Semin Oncol Nurs. 2018 May;34(2):137-150. doi: 10.1016/j.soncn.2018.03.005. Epub 2018 Apr 6. Review.

9.

What is the Role of Tumor-treating Fields in Newly Diagnosed Glioblastoma?

Ornelas AS, Porter AB, Sharma A, Knox MG, Marks LA, Wingerchuk DM, O'Carroll CB.

Neurologist. 2019 Mar;24(2):71-73. doi: 10.1097/NRL.0000000000000222.

PMID:
30817495
10.

Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.

Stupp R, Taillibert S, Kanner AA, Kesari S, Steinberg DM, Toms SA, Taylor LP, Lieberman F, Silvani A, Fink KL, Barnett GH, Zhu JJ, Henson JW, Engelhard HH, Chen TC, Tran DD, Sroubek J, Tran ND, Hottinger AF, Landolfi J, Desai R, Caroli M, Kew Y, Honnorat J, Idbaih A, Kirson ED, Weinberg U, Palti Y, Hegi ME, Ram Z.

JAMA. 2015 Dec 15;314(23):2535-43. doi: 10.1001/jama.2015.16669.

11.

Planning TTFields treatment using the NovoTAL system-clinical case series beyond the use of MRI contrast enhancement.

Connelly J, Hormigo A, Mohilie N, Hu J, Chaudhry A, Blondin N.

BMC Cancer. 2016 Nov 4;16(1):842.

12.

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma.

Riley MM, San P, Lok E, Swanson KD, Wong ET.

J Vis Exp. 2019 Apr 16;(146). doi: 10.3791/58937.

PMID:
31058901
13.
14.

Alternating Electric Fields (TTFields) Activate Cav1.2 Channels in Human Glioblastoma Cells.

Neuhaus E, Zirjacks L, Ganser K, Klumpp L, Schüler U, Zips D, Eckert F, Huber SM.

Cancers (Basel). 2019 Jan 18;11(1). pii: E110. doi: 10.3390/cancers11010110.

15.

Functional Biological Activity of Sorafenib as a Tumor-Treating Field Sensitizer for Glioblastoma Therapy.

Jo Y, Kim EH, Sai S, Kim JS, Cho JM, Kim H, Baek JH, Kim JY, Hwang SG, Yoon M.

Int J Mol Sci. 2018 Nov 21;19(11). pii: E3684. doi: 10.3390/ijms19113684.

16.

Tumor treating fields increases membrane permeability in glioblastoma cells.

Chang E, Patel CB, Pohling C, Young C, Song J, Flores TA, Zeng Y, Joubert LM, Arami H, Natarajan A, Sinclair R, Gambhir SS.

Cell Death Discov. 2018 Dec 5;4:113. doi: 10.1038/s41420-018-0130-x. eCollection 2018.

17.

Optune®: Practical Nursing Applications.

Murphy J, Bowers ME, Barron L.

Clin J Oncol Nurs. 2016 Oct 1;20(5 Suppl):S14-9. doi: 10.1188/16.CJON.S1.14-19. Review.

18.

Tumor treating fields: a new standard treatment for glioblastoma?

Taillibert S, Le Rhun E, Chamberlain MC.

Curr Opin Neurol. 2015 Dec;28(6):659-64. doi: 10.1097/WCO.0000000000000250. Review.

PMID:
26551239
19.

Alternating electric fields (TTFields) in combination with paclitaxel are therapeutically effective against ovarian cancer cells in vitro and in vivo.

Voloshin T, Munster M, Blatt R, Shteingauz A, Roberts PC, Schmelz EM, Giladi M, Schneiderman RS, Zeevi E, Porat Y, Bomzon Z, Urman N, Itzhaki A, Cahal S, Kirson ED, Weinberg U, Palti Y.

Int J Cancer. 2016 Dec 15;139(12):2850-2858. doi: 10.1002/ijc.30406. Epub 2016 Sep 19.

20.

Modelling Tumor Treating Fields for the treatment of lung-based tumors.

Bomzon Z, Urman N, Wenger C, Giladi M, Weinberg U, Wasserman Y, Kirson ED, Miranda PC, Palti Y.

Conf Proc IEEE Eng Med Biol Soc. 2015;2015:6888-91. doi: 10.1109/EMBC.2015.7319976.

PMID:
26737876

Supplemental Content

Support Center